The United States Patent and Trademark Office has issued US Patent No. 8,071,127 regarding formulations of inhaled liposomal and free ciprofloxacin to Aradigm Corporation. The patent covers the company's lead candidate, Pulmaquin dual release ciprofloxacin for inhalation, and should provide exclusivity for the product until October 22, 2027. Aradigm now plans to take … [Read more...] about Aradigm gets patents for inhaled ciprofloxacin formulations, announces plans for Pulmaquin Phase 3 trials
News
Decision Resources predicts flat asthma drug market through 2020
A report from research firm Decision Resources predicts no growth in the asthma drug market through 2020, in large part due to incursions by generics and greater competition. According to the company, "The overall asthma drug market will decrease slightly from $14.6 billion in 2010 to $14.4 billion in 2020 in the United States, France, Germany, Italy, Spain, the … [Read more...] about Decision Resources predicts flat asthma drug market through 2020
NanoBio to collaborate with Merck on intranasal RSV vaccine
Merck and NanoBio will conduct preclinical studies to evaluate a vaccine combining Merck's respiratory syncyctial virus (RSV) antigen with NanoBio's NanoStat adjuvant. NanoBio has already conducted studies that showed the induction of immunity by a NanoStat-adjuvanted RSV vaccine "without eliciting the enhanced respiratory disease that has caused other RSV vaccine … [Read more...] about NanoBio to collaborate with Merck on intranasal RSV vaccine
Powder Flow 2011 poster prize awarded to Hanne Kinnunen
The prize for the best poster presented at PowderFlow 2011 was awarded to Hanne Kinnunen, a PhD student in the Pharmaceutical Surface Science Research Group, Department of Pharmacy and Pharmacology at the University of Bath, for her poster titled, "The impact of loaded drug dose and the surface roughness of the coarse lactose carrier to the fluidisation … [Read more...] about Powder Flow 2011 poster prize awarded to Hanne Kinnunen
Aptar introduces new metering valve at DDL 22
Aptar Pharma launched its new DF30Plus metering valve, an extension of its DF30 line, at DDL 22. According to the company, the new valve is more compatible with a wide range of formulations, including those containing ethanol, and also has "ultra-low extractable levels" and "excellent pressure filling capability." Aptar Pharma Prescription Division's Associate … [Read more...] about Aptar introduces new metering valve at DDL 22
Positive Phase 2b results for Pearl’s PT001
Pearl Therapeutics has announced positive top-line results from a Phase 2b dose-ranging study of its PT001 glycopyrrolate (GP) MDI in patients with moderate-to-severe COPD. The randomized, double-blind study compared 4 doses of the PT001 MDI to placebo and to Atrovent HFA inhalation aerosol. According to Pearl all of the doses of GP tested demonstrated statistically … [Read more...] about Positive Phase 2b results for Pearl’s PT001
Meda gets patent related to Astepro nasal spray
Swedish pharma company Meda released a statement regarding a new patent for its Astepro nasal spray that reads in its entirety: "The United States Patent and Trademark Office (USPTO) today issued a patent related to Astepro (azelastine) nasal spray. This patent will be listed in the FDA's Approved Drug Products List (the Orange Book). The Astepro patent is valid … [Read more...] about Meda gets patent related to Astepro nasal spray
Bespak reports growth in 2011, deal for nicotine delivery device
Consort Medical, parent company of device developer and manufacturer Bespak, reports "strong volume growth" for Bespak's inhaler business for the six months ending October 31, 2011. Bespak revenues were up 17% from 2010, with operating profits up 24%. The company also announced a new contract for a nicotine delivery device to be distributed by a subsidiary of British … [Read more...] about Bespak reports growth in 2011, deal for nicotine delivery device
Acacia Research acquires inhaler technology
Acacia Research, a California company frequently described as a "patent troll," says that it has acquired 13 patents for inhaler technology from "a major medical company." Company CEO Paul Ryan said, “Acacia continues to increase the number of patent portfolios we control in the medical technology sector.” The type of inhaler covered by the patents was not … [Read more...] about Acacia Research acquires inhaler technology
Bloomberg highlights changes in GSK respiratory drug research
Bloomberg has published an article about GSK's overhaul of its R&D organization that describes former head of the allergic inflammation discovery performance unit Roberto Solari as "one of the casualties of the company’s new approach to drug discovery." According to the article, a spokesperson for GSK confirmed that Solari, whom the author describes as "an unassuming … [Read more...] about Bloomberg highlights changes in GSK respiratory drug research